Pictet Asset Management (UK)’s Coherus Oncology CHRS Stock Holding History

Pictet Asset Management (UK)’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$2.19M	Sell	158,575 -20,863	-12%	-$295K	﹤0.01%	993
2021 Q1	$2.62M	Buy	179,438 +4,740	+3%	+$80.5K	﹤0.01%	950
2020 Q4	$3.04M	Sell	174,698 -11,300	-6%	-$201K	﹤0.01%	917
2020 Q3	$3.41M	Sell	185,998 -4,300	-2%	-$80K	0.01%	808
2020 Q2	$3.4M	Sell	190,298 -16,900	-8%	-$286K	0.01%	778
2020 Q1	$3.36M	Buy	207,198 +94,900	+85%	+$1.75M	0.01%	742
2019 Q4	$2.02M	Buy	+112,298	New	+$2.07M	﹤0.01%	930
2018 Q2	–	Sell	-66,906	Closed	-$739K	–	888
2018 Q1	$739K	Hold	66,906	–	–	﹤0.01%	837
2017 Q4	$589K	Buy	66,906 +3,773	+6%	+$40.4K	﹤0.01%	845
2017 Q3	$843K	Buy	63,133 +37,942	+151%	+$502K	﹤0.01%	838
2017 Q2	$498K	Sell	25,191 -416,597	-94%	-$8.01M	﹤0.01%	843
2017 Q1	$9.34M	Buy	441,788 +1,432	+0.3%	+$35.2K	0.03%	483
2016 Q4	$12.4M	Buy	440,356 +60,264	+16%	+$1.69M	0.05%	404
2016 Q3	$10.2M	Buy	+380,092	New	+$10.4M	0.04%	426

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pictet Asset Management (UK)'s CHRS Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Coherus Oncology (CHRS) stake by 12% in Q2 2021, selling an estimated $295K and leaving 158,575 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #993.

Pictet Asset Management (UK) first reported a position in CHRS in Q3 2016 and has held it in 14 quarters since. The position peaked at $12.4M in Q4 2016. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

Pictet Asset Management (UK) held 158,575 shares of Coherus Oncology worth $2.19M as of Q2 2021.
Pictet Asset Management (UK) sold 20,863 Coherus Oncology shares in Q2 2021, an estimated $295K.
Coherus Oncology made up ﹤0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #993 holding.
Pictet Asset Management (UK) first reported a position in Coherus Oncology in Q3 2016 and has held it in 14 quarters since.
Pictet Asset Management (UK)'s Coherus Oncology position peaked at $12.4M in Q4 2016.
188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.